Anil Champalal Jain, Managing Director and member of the promoter group of Bajaj Healthcare , acquired 1,00,000 equity shares through an open market transaction on June 12, 2026. The acquisition increases the promoter group's stake in the pharmaceutical company, reflecting a direct addition to their shareholding.

Transaction Details

The disclosure was submitted to the exchanges under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The key details of the transaction are outlined below:

Shareholding Pattern

Following the acquisition, the total shareholding of the acquirer along with Persons Acting in Concert (PAC) has increased. The table below details the holding before and after the transaction:

The total paid-up equity share capital of Bajaj Healthcare Limited stands at 3,36,62,661 equity shares of ₹5 each, aggregating to ₹16,83,13,305. The shares of the company are listed on BSE Limited and National Stock Exchange of India Limited.

Bajaj Healthcare Limited reported its audited standalone financial results for the quarter and financial year ended March 31, 2026, as approved by its Board of Directors at a meeting held on May 08, 2026. The results were audited by Walker Chandiok & Co LLP, Chartered Accountants, with an unmodified opinion, and reviewed by the Audit Committee prior to board approval. In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audited financial results were subsequently published in Financial Express and Mumbai Lakshadweep on May 10, 2026. The company, a leading manufacturer of APIs, Intermediates, and Formulations established in 1993, operates in a single reportable segment — Pharmaceuticals — encompassing formulations and active pharmaceutical ingredients.

Financial Performance: FY26 vs FY25

Bajaj Healthcare's revenue from operations for the full year ended March 31, 2026 grew 12.6% to ₹61,103.14 lakhs from ₹54,260.24 lakhs in the previous year. Total income for FY26 stood at ₹61,816.53 lakhs against ₹56,200.68 lakhs in FY25. EBITDA for FY26 came in at Rs. 1,119.5 Mn, up 9.9% YoY, with EBITDA margin at 18.3% compared to 18.8% in FY25. Profit After Tax (PAT) from continuing operations before exceptional items grew 27.1% YoY to Rs. 545.6 Mn, with PAT margin from continuing operations improving to 8.8% from 7.9% in FY25. However, reported net profit for the year declined to ₹1,576.61 lakhs from ₹3,949.55 lakhs, primarily due to an exceptional item of ₹3,324.66 lakhs — the reversal of technical know-how income recognised in an earlier year, attributable to ongoing regional instability in the Middle East that prevented a customer from meeting its committed timeline. Profit before exceptional items and tax for FY26 was ₹6,216.96 lakhs, compared to ₹4,600.77 lakhs in FY25, reflecting underlying operational improvement.

The following table summarises the key financial metrics for the year and the most recent quarter:

Revenue Breakup

FY26 revenue growth was driven by strong API export performance and sustained momentum in formulations. API exports surged 51.6% YoY to Rs. 1,881.4 Mn for the full year, while formulations grew 12.6% YoY to Rs. 1,033.2 Mn. Domestic API revenue saw a modest decline of 2.2% YoY to Rs. 3,195.7 Mn, reflecting continued price erosion in the domestic market.

Earnings Per Share

The earnings per share figures for FY26 and FY25 reflect the impact of the exceptional item and discontinued operations on the full-year results.

Discontinued Operations and Asset Disposals

The company has classified certain manufacturing units and industrial land as assets held for sale under Ind AS 105. During the quarter ended March 31, 2026, one unit situated at plot no. L-9/3, MIDC Tarapur was sold. Loss after tax from discontinued operations for FY26 stood at ₹554.43 lakhs, compared to ₹343.33 lakhs in FY25. Non-current assets classified as held for sale stood at ₹6,993.00 lakhs as at March 31, 2026.

Preferential Issue and Fund Utilisation

On March 18, 2026, the Board approved the allotment of 20,79,409 fully paid-up equity shares at a price of ₹338 per share (including a premium of ₹333) pursuant to the conversion of warrants, bringing additional capital of INR 527 million to strengthen the balance sheet. Earlier, on September 19, 2024, the company had allotted 39,84,852 equity shares and 20,79,409 convertible warrants, raising an aggregate amount of ₹15,225.90 lakhs. The utilisation of funds raised through the preferential issue is detailed below:

Key Business Developments

Bajaj Healthcare made notable progress on the regulatory and product development front during the period. Cenobamate, a novel anti-epileptic molecule, is progressing through Phase III clinical trials as planned and is slated for launch in Q2 FY27, strengthening the company's presence in the CNS space. The company also successfully completed the bioequivalence study for Suvorexant Tablets and will be filing the application with DCGI in the near term. On the regulatory filing front, 41 Drug Master Files (DMFs) were filed in Q4, bringing the cumulative total to 110, further reinforcing the company's global regulatory presence in regulated and high-value markets.

Dividend, Auditor Appointments, and Acquisition Update

The Board recommended a final dividend of ₹1.50 per equity share (30% of face value of ₹5 each) for FY26, subject to shareholder approval at the ensuing Annual General Meeting. The paid-up equity share capital as at March 31, 2026 stood at ₹1,683.13 lakhs, with other equity at ₹51,617.10 lakhs. The Board also approved the appointment of M/s. JCR & Co. LLP, Chartered Accountants, as Internal Auditors for FY2026-27, and the re-appointment of M/s. V.J. Talati & Co., Cost Accountants, as Cost Auditors for FY2026-27. Separately, in April 2025, the company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) on a going concern basis for a total consideration of ₹1,085 lakhs; however, Genrx has not been consolidated as a subsidiary pending requisite approvals from the National Company Law Tribunal, Mumbai, as control under Ind AS 110 has not yet been established.

Management Commentary

Commenting on the results, Mr. Anil Jain, Managing Director, said: "The quarter was marked by a challenging operating environment driven by continued price erosion in domestic APIs, early impacts of geopolitical disruptions in West Asia including elevated raw material prices. While revenue remained broadly stable on a YoY basis despite high teens volume growth, Profit After Tax from continuing operations before exceptional items registered healthy growth of 19% YoY, reflecting the strength of our operational discipline, cost management, and continued focus on profitability despite external headwinds. FY26 revenue grew 12.6% YoY, driven by strong API export growth of 51.6% YoY as we witnessed healthy traction across the EU, UK, LATAM, and other regulated markets, coupled with sustained momentum in the formulations business which also recorded 12.6% YoY growth. Looking ahead, we remain focused on strengthening our core API business and achieving export-led growth while scaling our formulations business with an emphasis on higher-value products. We are accelerating efforts in peptides, oncology, and CNS, supported by continued investments in manufacturing, capacity expansion, and R&D-led innovation."

Source: None/Company/INE411U01027/389412c4b56747a7.pdf